CSIMarket
 


Aclaris Therapeutics Inc   (ACRS)
Other Ticker:  
 

Aclaris Therapeutics Inc 's Tangible Leverage Ratio

ACRS's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth




ACRS Tangible Leverage Ratio (Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Tangible Equity Change 1.59 % 0.89 % 64.63 % 523.36 % 523.28 %
Y / Y Total Liabilities Change 1.04 % -23.67 % -5.7 % 63.28 % 52.13 %
Tangible Leverage Ratio MRQ 0.22 0.18 0.27 0.28 0.22
Overall Ranking # # # # #
Seq. Tangible Equity Change -6.95 % 32.09 % -9 % -9.17 % -7.59 %
Seq. Total Liabilities Change 14.38 % -10.54 % -14.1 % 14.95 % -13.59 %



Tangible Leverage Ratio third quarter 2022 Comment
Due to net new borrowings of 14.38%, Tangible Leverage Ratio detoriated to 0.22, above company's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry Aclaris Therapeutics Inc achieved lowest Tangible Leverage Ratio. While total ranking remained unchanged compare to previous quarter at no. .

Explain Tangible Leverage Ratio?
What is ACRS Market Share?
Tangible Leverage Ratio third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Tangible Leverage Ratio Statistics
High Average Low
0 0 0
 




Financial Statements
Aclaris Therapeutics Inc 's Tangible Equity $ 213 Millions Visit ACRS's Balance sheet
Aclaris Therapeutics Inc 's Total Liabilities $ 47 Millions Visit ACRS's Balance sheet
Source of ACRS's Sales Visit ACRS's Sales by Geography


Cumulative Aclaris Therapeutics Inc 's Tangible Leverage Ratio

ACRS's Tangible Leverage Ratio for the trailling 12 Months

ACRS Tangible Leverage Ratio

(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
Y / Y Tangible Equity TTM Growth 1.59 % 0.89 % 64.63 % 523.36 % 523.28 %
Y / Y Total Liabilities TTM Growth 1.04 % -23.67 % -5.7 % 63.28 % 52.13 %
Tangible Leverage Ratio TTM 0.23 0.23 0.25 0.28 0.32
Total Ranking TTM # 530 # 580 # 622 # 159 # 696
Seq. Tangible Equity TTM Growth -6.95 % 32.09 % -9 % -9.17 % -7.59 %
Seq. Total Liabilities TTM Growth 14.38 % -10.54 % -14.1 % 14.95 % -13.59 %


TTM Tangible Leverage Ratio Comment
On the trailing twelve months basis Despite of the net new borrowings of 14.38% Aclaris Therapeutics Inc managed to unchange Tangible Leverage Ratio in III. Quarter to 0.23, a new company low.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 178 other companies have achieved lower Tangible Leverage Ratio than Aclaris Therapeutics Inc . While total ranking remained unchanged compare to previous quarter at no. 530.

Explain Tangible Leverage Ratio?
What is ACRS Market Share?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 179
Healthcare Sector # 301
Within the Market # 530


TTM Tangible Leverage Ratio Statistics
High Average Low
0.75 0.45 0.23
(Dec 31 2020)   (Jun 30 2022)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioSep 30 2022 MRQ Total LiabilitiesSep 30 2022 MRQ Tangible Equity
Nature s Sunshine Products inc   0.61 $ 85.766  Millions$ 141.754  Millions
Alpine Immune Sciences Inc   0.60 $ 109.590  Millions$ 182.009  Millions
Iterum Therapeutics Plc  0.60 $ 18.089  Millions$ 30.401  Millions
Pds Biotechnology Corp  0.59 $ 27.828  Millions$ 47.059  Millions
Applied Molecular Transport Inc   0.59 $ 46.212  Millions$ 78.395  Millions
Macrogenics Inc   0.59 $ 72.389  Millions$ 122.958  Millions
Medavail Holdings Inc   0.57 $ 16.807  Millions$ 29.726  Millions
23andme Holding Co   0.55 $ 221.412  Millions$ 402.648  Millions
Scpharmaceuticals Inc   0.53 $ 16.582  Millions$ 31.110  Millions
Vaxxinity Inc   0.53 $ 42.699  Millions$ 80.261  Millions
Aptinyx Inc   0.52 $ 25.193  Millions$ 48.792  Millions
Aditxt Inc   0.52 $ 6.485  Millions$ 12.561  Millions
Cyclerion Therapeutics Inc   0.52 $ 8.529  Millions$ 16.524  Millions
Nighthawk Biosciences inc   0.51 $ 35.699  Millions$ 70.625  Millions
Cue Biopharma Inc   0.50 $ 25.536  Millions$ 50.764  Millions
Cellectar Biosciences Inc   0.50 $ 6.367  Millions$ 12.751  Millions
Lexicon Pharmaceuticals Inc   0.48 $ 47.667  Millions$ 99.475  Millions
Eyenovia inc   0.48 $ 9.692  Millions$ 20.329  Millions
Amphastar Pharmaceuticals Inc   0.47 $ 221.530  Millions$ 468.128  Millions
Decibel Therapeutics Inc   0.47 $ 45.459  Millions$ 96.814  Millions
Prophase Labs Inc   0.46 $ 24.692  Millions$ 53.323  Millions
Metacrine Inc   0.46 $ 17.109  Millions$ 37.065  Millions
Transcode Therapeutics Inc   0.45 $ 3.748  Millions$ 8.244  Millions
Adial Pharmaceuticals Inc   0.45 $ 2.333  Millions$ 5.155  Millions
Beigene Ltd   0.45 $ 2,070.842  Millions$ 4,614.322  Millions
Biohaven Ltd   0.44 $ 35.430  Millions$ 80.426  Millions
Biomarin Pharmaceutical Inc  0.42 $ 1,695.526  Millions$ 4,018.291  Millions
Integrated Biopharma Inc  0.42 $ 7.743  Millions$ 18.621  Millions
Acadia Pharmaceuticals Inc   0.42 $ 176.805  Millions$ 425.686  Millions
Cyclacel Pharmaceuticals Inc   0.41 $ 8.954  Millions$ 22.067  Millions

Date modified: 2022-11-10T19:59:29+00:00

Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

GIGA's Profile

Stock Price

GIGA's Financials

Business Description

Fundamentals

Charts & Quotes

GIGA's News

Suppliers

GIGA's Competitors

Customers & Markets

Economic Indicators

GIGA's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071